Generaal De Wittelaan L11 A3
Mechelen 2800
Belgium
32 1 534 29 00
https://www.glpg.com
Settore/i:
Settore:
Impiegati a tempo pieno: 1.123
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman, Interim Head of R&D | 1,26M | N/D | 1962 |
Mr. Thad Huston | Executive VP, CFO & COO | N/D | N/D | 1971 |
Ms. Sofie Van Gijsel | Head of Investor Relations | N/D | N/D | N/D |
Ms. Valeria Cnossen | Executive VP & General Counsel | N/D | N/D | 1974 |
Marieke Vermeersch | Head of Corporate Communication | N/D | N/D | N/D |
Ms. Annelies Missotten | Executive VP & Chief Human Resources Officer | N/D | N/D | 1973 |
Ms. Ellen Van Der Aar | Head of Development | N/D | N/D | N/D |
Mr. Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Business Development | N/D | N/D | N/D |
Mr. Dirk De Naeyer | Head of Development Operations | N/D | N/D | N/D |
Ms. Alice Dietrich | Head of Medical Affairs | N/D | N/D | N/D |
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
L'ISS Governance QualityScore di Galapagos NV al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 4; diritti degli azionisti: 4; retribuzione: 10.